Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Christopher G. Kanakry, Marcos J. de Lima, Leo Luznik

Research output: Contribution to journalReview articlepeer-review

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) provides a potentially curative therapy for patients with high-risk or chemorefractory acute myeloid leukemia (AML). Historically, the applicability of alloHCT has been limited as only 30%-35% of patients have human leukocyte antigen (HLA)-matched siblings and outcomes using other donor types have been markedly inferior due to excess toxicity, graft failure, graft-versus-host disease (GVHD), and consequently non-relapse mortality. Advances in HLA typing, GVHD prophylactic approaches, and other transplantation techniques have successfully addressed these historical challenges. Herein, we review recent alloHCT studies using volunteer unrelated donors, umbilical cord blood units, or HLA-haploidentical donors, specifically focusing on studies that compared outcomes between donor sources. Although none are randomized and most are retrospective, these analyses suggest that current outcomes for AML patients using most alternative donor types are comparable to those seen using HLA-matched siblings.

Original languageEnglish (US)
Pages (from-to)232-242
Number of pages11
JournalSeminars in Hematology
Volume52
Issue number3
DOIs
StatePublished - Jul 1 2015

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this